Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9140412 | 0.75 | PARP1 (0.47) | PARP1 | |
| SCHEMBL16621278 | 0.72 | PARP1 (0.47) | PARP1 | |
| SCHEMBL28067181 | 0.72 | PARP1 (0.47) | PARP1 | |
| SCHEMBL14820465 | 0.72 | PARP1 (0.47) | PARP1 | |
| SCHEMBL13833540 | 0.72 | PARP1 (0.47) | PARP1 | |
| SCHEMBL27809382 | 0.70 | PARP1 (0.42) | PARP1 | |
| SCHEMBL20120194 | 0.70 | TDP1 (0.42) | PARP1 | |
| SCHEMBL31386914 | 0.69 | PARP1 (0.41) | PARP1 | |
| SCHEMBL4442482 | 0.69 | AURKA (0.47) | PARP1 | |
| SCHEMBL19495415 | 0.68 | PARP1 (0.40) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5516941-A | OXIDIZING 3-AMINOBENZAMIDE TO 3-NITROSOBENZAMIDE; VIRICIDES; ANTICARCINOGENIC AND ANTITUMOR AGENTS | OCTAMER, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0666742-A1 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-RETROVIRAL AGENTS AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009776-A1 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-RETROVIRAL AGENTS AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1994-05-11 | — | — | WO | disclosed |